酪氨酸激酶抑制剂在HER2阳性转移性乳腺癌治疗中的作用
本文综述了靶向HER2及其他HER家族受体的酪氨酸激酶抑制剂(TKI)在HER2阳性转移性乳腺癌三线及后线治疗中的作用。拉帕替尼、来那替尼和图卡替尼已获监管批准,吡咯替尼和阿法替尼也在该领域进行了评估。TKI对中枢神经系统转移显示出不同程度疗效,但需管理腹泻、手足综合征和皮疹等毒性。
要点
- HER2阳性转移性乳腺癌三线及后线无标准治疗,推荐继续抗HER2治疗。
- 拉帕替尼、来那替尼、图卡替尼已获批,吡咯替尼和阿法替尼在评估中。
- TKI对中枢神经系统转移有不同程度疗效,需管理腹泻、手足综合征和皮疹。
核心结论
- TKI在HER2阳性转移性乳腺癌三线及后线治疗中起核心作用,对中枢神经系统转移有不同程度疗效。
研究设计与样本
- 本文为综述,汇总了TKI在HER2阳性转移性乳腺癌中的疗效和安全性数据。
主要发现
- 拉帕替尼、来那替尼和图卡替尼已获监管批准用于HER2阳性转移性乳腺癌。
- 吡咯替尼和阿法替尼已在HER2阳性转移性乳腺癌中进行了评估。
- TKI对中枢神经系统转移显示出不同程度疗效。
- 临床试验中报告的需特定管理策略的毒性包括腹泻、手足综合征和皮疹。
临床怎么用
- 可将TKI纳入HER2阳性转移性乳腺癌治疗算法,尤其三线及后线。
- 需针对腹泻、手足综合征和皮疹等不良事件制定管理策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The introduction of trastuzumab and other subsequent human epidermal growth factor receptor 2 (HER2)-targeted therapies dramatically shifted the treatment landscape of HER2+ breast cancer, changing the natural history of the disease. There is no standard-of-care for patients with HER2+ metastatic breast cancer (MBC) in third and later lines of treatment; however, continued use of anti-HER2 therapies is recommended. Small-molecule tyrosine kinase inhibitors (TKIs) that target HER2 and other HER family receptors play a central role in this setting. TKIs have demonstrated various degrees of efficacy against central nervous system (CNS) metastases, which are a major clinical challenge for patients with HER2+ MBC. The TKIs lapatinib, neratinib, and tucatinib have received regulatory approval for the treatment of HER2+ MBC, while pyrotinib and afatinib have been evaluated in this setting. These TKIs vary by molecular weight, HER protein specificity and reversibility of binding and in turn have unique safety profiles. Toxicities reported in clinical trials of TKIs in HER2+ MBC that may require specific management strategies include diarrhoea, palmar-plantar erythrodysesthesia syndrome and rash. Here, we review the efficacy data, including CNS activity, and the safety profiles of the TKIs, and we provide guidance on adverse event management. Finally, we discuss how to incorporate the TKIs into the HER2+ MBC treatment algorithm.
引用
- Le Du F, Diéras V, Curigliano G, et al. The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer. Eur J Cancer. 2021. PMID: 34280871. doi:10.1016/j.ejca.2021.06.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。